Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q2 2024 · 10-Q
Revenue$1.05M$1.05M−79.9% vs Q2 2023 Net Income-$5.33M-$5.33MN/M vs Q2 2023 EPS Diluted-$4.34-$4.34N/M vs Q2 2023 Gross Profit$244,430−86.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,430,136N/M Margins · derivedGross margin23.4%−10.9 pt vs Q2 2023
Operating margin-352.6%−271.3 pt vs Q2 2023
Net margin-508.9%−400.9 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 14, 2024 · 45 d after period end